Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Outcomes of nivolumab (NIVO)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC) in United States community oncology practice.
Authors
Eric Nadler
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
Eric Nadler, Janet Espirito, Thomas Wilson, Komal Gupte-Singh, Sumati Rao, Beata Korytowsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 119)
DOI
10.1200/JCO.2019.37.8_suppl.119
Abstract #
119
Poster Bd #
H3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2023 ASCO Annual Meeting
Treatment patterns and unmet need for patients with advanced non-small cell lung cancer and poor performance status: A real-world evidence study.
First Author: Stephen V. Liu
Poster
2020 ASCO Virtual Scientific Program
PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC).
First Author: Deborah Blythe Doroshow
Poster
2017 ASCO Annual Meeting
Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy.
First Author: Saveri Bhattacharya